Evidence map›Paper›PMID 39450470›Full record

ArticleHuman gene therapy2024

Adeno-Associated Virus Gene Transfer Ameliorates Progression of Skeletal Lesions in Mucopolysaccharidosis IVA Mice.

Angélica María Herreño-Pachón, Kazuki Sawamoto, Molly Stapleton, Shaukat Khan, Matthew Piechnik, Jose Victor Álvarez, Shunji Tomatsu

Abstract read
In one paragraph

Article in Human gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Advances in Therapies for Mucopolysaccharidoses.Current issues in molecular biology · 2026
    Review
  3. Recent advances in mucopolysaccharidosis IVA treatment.Orphanet journal of rare diseases · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Angélica María Herreño-PachónNemours Children's Health, Wilmington, Delaware, USA.
Kazuki SawamotoNemours Children's Health, Wilmington, Delaware, USA.
Molly StapletonNemours Children's Health, Wilmington, Delaware, USA.
Shaukat KhanNemours Children's Health, Wilmington, Delaware, USA.
Matthew PiechnikNemours Children's Health, Wilmington, Delaware, USA.
Jose Victor ÁlvarezNemours Children's Health, Wilmington, Delaware, USA.
Shunji TomatsuNemours Children's Health, Wilmington, Delaware, USA.ORCID 0000-0002-0673-2160

Funding

Non-invasive functional assessment and pathogenesis of Morquio AR01HD102545 · NICHD · NEMOURS CHILDREN'S HOSPITAL, DELAWARE · PI TOMATSU, SHUNJI · 2021 to 2025
$2.9M
NICHD NIH HHS R01 HD102545
6 · The paper itself

Abstract

Mucopolysaccharidosis type IVA (MPS IVA) is an autosomal congenital metabolic lysosomal disease caused by a deficiency of the

Indexed as

ChondroitinsulfatasesDependovirusDisease Models, AnimalGenetic TherapyGenetic VectorsMucopolysaccharidosis IVAnimalsBone and BonesDisease ProgressionGene Transfer TechniquesHumansLiverMicePromoter Regions, GeneticChondroitinsulfatasesGALNS protein, humanAAVGALNSgene therapykeratan sulfateMPS IVAskeletal dysplasia

Identifiers

PMID39450470
PMCPMC11659441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.